Biologics: Targets and Therapy
Volume 12, 2018 - Issue
Open access
77
Views
6
CrossRef citations to date
0
Altmetric
Original Research
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
Yusuf Yazici1 Rheumatology, New York University, School of Medicine, New York, NY, USA
, Lin Xie2 Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA, [email protected]
, Adesuwa Ogbomo2 Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA, [email protected]Correspondence[email protected]
, Lorie A Ellis3 Real World Value and Evidence, Janssen Scientific Affairs, Titusville, NJ, USA
, Kavitha Goyal4 Immunology Medical Affairs, Janssen Biotech Incorporated, Horsham, PA, USA
, Amanda Teeple5 Health Economics and Outcomes Research, Jassen Scientific Affairs, LLC, Horsham, PA, USA
& Ismail Simsek6 Department of Rheumatology, Guven Hospital, Ankara, Turkey
show all
Pages 127-134
|
Published online: 25 Oct 2018
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.